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Abstract 
Background: Increasing age is a strong, independent, risk factor for atherosclerosis and 
cardiovascular disease. Key abnormalities driving cardiovascular risk in old age include 
endothelial dysfunction, increased arterial stiffness and blood pressure, and the pro-
atherosclerotic effects of chronic, low-grade, inflammation. The identification of novel 
therapies that comprehensively target these alterations might lead to a major breakthrough in 
cardiovascular risk management in the older population. Systematic reviews and meta-
analyses of observational studies have shown that methotrexate, a first-line synthetic disease-
modifying anti-rheumatic drug, significantly reduces cardiovascular morbidity and mortality 
in patients with rheumatoid arthritis, a human model of systemic inflammation, premature 
atherosclerosis, and vascular ageing.  
Methods and results: We reviewed the in vitro and in vivo studies investigating the effects of 
methotrexate on endothelial function, arterial stiffness, and blood pressure, and the potential 
mechanisms of action involved. The available evidence suggests that methotrexate might 
exert beneficial effects on vascular homeostasis and blood pressure control by targeting 
specific inflammatory pathways, adenosine metabolism, and 5' adenosine monophosphate-
activated protein kinase. Such effects might be biologically and clinically relevant not only in 
patients with rheumatoid arthritis but also in older adults at high cardiovascular risk. 
Conclusions: Methotrexate has the potential to be repurposed for cardiovascular risk 
management in old age in view of its putative pharmacological effects on inflammation, 
vascular homeostasis, and blood pressure. However, the further study and confirmation of 
these effects are essential in order to adequately design intervention studies of methotrexate in 
the older population.  
Key words: methotrexate, cardiovascular risk, ageing, atherosclerosis, endothelium, arterial 
stiffness, blood pressure, inflammation.  
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1. INTRODUCTION 
Atherosclerotic cardiovascular disease remains the leading cause of death worldwide in spite 
of significant advances in diagnosis, treatment, and prevention [1]. Two clinical 
manifestations of atherosclerotic cardiovascular disease, ischaemic heart disease and 
cerebrovascular disease, account for about 85% of all cardiovascular disease deaths [1]. 
Cardiovascular disease primarily affects the older population because of the lifelong 
accumulation of risk factors and the development of significant functional and structural 
alterations of the arterial wall that favour the development of atherosclerosis and thrombosis 
in this group [2-4]. Experimental and clinical evidence has also highlighted the important 
pathophysiological role of inflammation, driven by specific pro-atherosclerotic cytokines, in 
favouring vascular damage and atherosclerosis [4, 5]. The role of inflammation is further 
supported by the recent identification of a new cardiovascular risk paradigm, residual 
inflammatory risk. This describes a relatively large group, between 29-47% of patients with 
atherosclerotic cardiovascular disease, with persistently high inflammatory risk markers and 
cardiovascular risk despite maximal treatment with cardioprotective drugs, particularly statins 
[6]. However, available cardiovascular drugs do not specifically target pro-atherosclerotic 
inflammatory pathways. The identification of new agents with anti-inflammatory and 
vasculoprotective effects might significantly improve primary and secondary cardiovascular 
prevention, particularly in patients with residual inflammatory risk [6-10]. While a significant 
amount of research is focused on the discovery of such agents the study of human models of 
premature atherosclerosis and vascular ageing, in the context of a chronic pro-inflammatory 
state, might lead to the identification of previously unknown vasculoprotective effects of 
currently available anti-inflammatory and immunomodulating drugs. Repurposing these drugs 
for cardiovascular risk management would circumvent the need for time-consuming, highly-
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expensive drug discovery and development programs, therefore facilitating their routine use 
in clinical practice [11].  
This review discusses the vascular alterations associated with ageing, and their similarities 
with those reported in rheumatoid arthritis, an autoimmune condition characterized by chronic 
systemic inflammation and high cardiovascular risk. It also discusses the epidemiological and 
clinical studies investigating the association between the use of the first-line disease 
modifying anti-rheumatic drug (DMARD) methotrexate and cardiovascular risk, the in vitro 
and in vivo studies on the vasculoprotective effects of methotrexate and the mechanisms 
involved, and the potential repurposing of this drug for cardiovascular risk management, 
particularly in the older patient population. 
 
2. VASCULAR AGEING: PATHOPHYSIOLOGY AND CLINICAL 
IMPLICATIONS 
The vascular alterations occurring with advancing age primarily consist of endothelial 
dysfunction and an increase in arterial stiffness and blood pressure in the context of a chronic, 
low-grade, non-specific pro-inflammatory state (Figure 1).  
2.1 Endothelial dysfunction 
The endothelium, primarily through the synthesis of the key messenger nitric oxide (NO) by 
the enzyme endothelial NO synthase (eNOS), plays a key role in the modulation of arterial 
stiffness, peripheral vascular resistance, and blood pressure. This is supported by 
experimental and human studies showing that the pharmacological inhibition of eNOS causes 
a significant increase in arterial stiffness, peripheral vascular resistance, and blood pressure 
[12-14]. The endothelium also exerts atheroprotective effects by preventing leukocyte 
adhesion, vascular smooth muscle cell hypertrophy and proliferation, and platelet aggregation 
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[15-17]. There is good evidence that advancing age per se is associated with reduced 
synthesis and/or increased degradation of endothelial NO [18, 19]. One possible reason for 
the impaired synthesis of NO is the reduced availability and/or oxidation of the critical eNOS 
cofactor tetrahydrobiopterin. This leads to the synthesis of superoxide, instead of NO, by 
“uncoupled” eNOS [20]. This phenomenon has been observed in experimental models of 
ageing [21, 22]. Another factor potentially involved in the reduced synthesis of NO with 
advancing age is represented by an increased activity of arginase, an enzyme that competes 
with eNOS for the substrate L-arginine [23]. Several studies have also investigated the factors 
responsible for the increased degradation of NO associated with ageing. In particular, the 
presence of high local concentrations of reactive oxygen species (ROS), in the context of 
chronic inflammation and stimulation of the cytokine tumour necrosis factor (TNF)-, and the 
activation of the renin-angiotensin-aldosterone system, are likely to favour excessive NO 
degradation [24-26]. In addition to the dysregulation of NO metabolic pathways, an 
imbalance between other endogenous vasodilators and vasoconstrictors, favouring 
vasoconstriction, arterial stiffening, and blood pressure elevation, has also been reported with 
advancing age. In particular, increasing concentrations of the endogenous vasoconstrictors 
endothelin-1, prostaglandin H2, and thromboxane A2, have been observed in experimental and 
human ageing [27-30]. Furthermore, an impairment of the vasodilating effects of prostacyclin 
has been reported with advancing age [31].  
High ROS concentrations can also favour endothelial cell senescence, a phenomenon 
characterized by the interruption of the cell cycle and specific phenotypic changes [32]. These 
alterations cause a further increase in the synthesis and release of inflammatory cytokines, 
mediated by the activation of specific pathways such as the nuclear factor NF-B, p38 
mitogen-activated protein kinases, the DNA damage response pathway, and the transcription 
factor GATA-4 [33, 34]. Therefore, endothelial cell senescence significantly contributes to 
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the pro-inflammatory state of the arterial wall and the development of vascular damage and 
atherosclerosis [35, 36]. 
2.2 Increased arterial stiffness and blood pressure 
The strong and independent association between advancing age and increased stiffness of the 
large conduit arteries, particularly the thoracic and abdominal aorta, is well documented [37]. 
The primary structural abnormalities underlying this phenomenon are represented by a 
reduction in elastic fibres and a concomitant increase in the amount of collagen in the arterial 
wall [38]. The accumulation of cardiovascular risk factors with ageing, particularly 
hypertension, has been proposed as the primary mechanism responsible for the increase in 
arterial stiffness, through an impairment in endothelial function and NO synthesis and an 
increase in sympathetic nervous system activity [39-44]. An additional factor that likely 
contributes to the increase in arterial stiffness with ageing is represented by a systemic pro-
inflammatory state [45]. Although the exact mechanisms responsible for the inflammation-
induced increase in arterial stiffness are unclear, the detrimental effect of specific 
inflammatory pathways on endothelial NO synthesis and the concomitant dysregulation of 
other pathways, such as the mechanistic target of rapamycin, the 5' adenosine 
monophosphate-activated protein kinase (AMPK), and sirtuins, might play a role [46-50].  
An increase in large artery stiffness causes a further increase in systolic blood pressure and a 
reduction in diastolic blood pressure, with a consequent increase in pulse pressure [51]. 
Markers of increased arterial stiffness, such as the augmentation index and pulse-wave 
velocity, and higher systolic and pulse pressure values increase cardiac afterload and 
independently predict cardiovascular morbidity and mortality in middle-age and older adults 
[52-55]. At the same time, a reduction in diastolic blood pressure might critically impair 
coronary perfusion, with the consequent risk of myocardial ischaemia and adverse 
cardiovascular outcomes [56, 57].   
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3. RHEUMATOID ARTHRITIS: A HUMAN MODEL OF PREMATURE 
VASCULAR AGEING AND ATHEROSCLEROSIS 
Rheumatoid arthritis is a chronic disabling autoimmune condition that is characterized by 
chronic local and systemic inflammation, joint pain, stiffness, and fatigue. Patients with 
rheumatoid arthritis also suffer from so-called “extra-articular” manifestations that affect 
several organs and systems and further contribute to disability and poor quality of life [58]. 
The disease-modifying anti-rheumatic drugs (DMARDs), cornerstone of treatment in 
rheumatoid arthritis, suppress the immune system, reduce local and systemic inflammation, 
and maintain physical and functional independence [58].   
Rheumatoid arthritis is associated with higher mortality compared to the general population 
[59]. The excess mortality in rheumatoid arthritis is primarily due to cardiovascular death, 
with a standardized mortality ratio of 1.46 compared to the general population [60]. It is 
postulated that the state of chronic systemic inflammation in rheumatoid arthritis, and the 
activation of pro-atherosclerotic cytokines such as TNF-, interleukin 1 (IL-1), and 
interleukin-6 (IL-6), favours endothelial dysfunction, vascular damage and atherosclerosis 
(Figure 1) [61-64]. However, traditional risk factors, such as hypertension, diabetes, obesity, 
and hypercholesterolaemia, also contribute to the pathogenesis of vascular dysfunction and 
the risk of adverse cardiovascular outcomes in this group [65].  
Endothelial dysfunction is common in rheumatoid arthritis and affects both macrovascular 
and microvascular beds [66, 67]. In particular, microvascular endothelial dysfunction affects 
approximately 33% of patients even in the absence of overt cardiovascular disease [61]. This 
might account for the reduced coronary flow reserve, and consequent increased risk of 
ischaemic heart disease, reported in patients with rheumatoid arthritis and other similar 
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autoimmune conditions [68]. In addition to the potential role of inflammatory pathways and 
traditional cardiovascular risk factors, the accumulation of the potent endogenous inhibitor of 
eNOS synthase, asymmetric dimethylarginine (ADMA), might also play a role in the 
pathogenesis of endothelial dysfunction in rheumatoid arthritis [69-71]. 
The presence of endothelial dysfunction, with the consequent impairment in NO synthesis, 
leads to an increase in arterial stiffness in patients with rheumatoid arthritis [72]. Age, disease 
duration and severity, rheumatoid factor status, systolic blood pressure, leukocyte count, 
cholesterol fractions, and use of TNF- inhibitors have shown independent associations with 
arterial stiffness in this group [73-75]. This suggests, similar to endothelial dysfunction, a 
combined contribution of specific disease markers, inflammatory markers and traditional 
cardiovascular risk factors to the pathogenesis of arterial stiffening in rheumatoid arthritis. An 
increase in arterial stiffness in rheumatoid arthritis exerts detrimental effects on blood 
pressure, cardiac afterload, and clinical outcomes that are similar to those described with 
ageing [76-78]. Studies on the relationship between rheumatoid arthritis and the incidence and 
prevalence of hypertension, when compared to the general population, have provided 
conflicting results [79]. However, recent evidence suggests sub-optimal diagnosis and 
undertreatment of hypertension in this group, with consequent adverse effects on arterial 
structure and function [80-82]. 
 
4. METHOTREXATE AND CARDIOVASCULAR DISEASE 
Methotrexate is a relatively old, first-line, DMARD for the treatment of rheumatoid arthritis 
[83]. Notably, it is the only synthetic DMARD that has been shown to significantly reduce 
cardiovascular and all-cause mortality in this group [84]. Several studies have investigated the 
associations between methotrexate treatment and cardiovascular risk, endothelial function, 
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arterial stiffness, and blood pressure, in patients with and without rheumatoid arthritis or other 
autoimmune disorders. 
4.1 Methotrexate and cardiovascular risk 
Two systematic reviews and meta-analyses of observational studies in patients with 
rheumatoid arthritis and other autoimmune disorders have reported a significant reduction in 
cardiovascular events with methotrexate. The first meta-analysis of 10 studies in 66,334 
patients showed that methotrexate use was associated with a significant reduction in total 
cardiovascular events (risk ratio, RR, 0.79, 95% CI 0.73 to 0.87) [85]. Similarly, the second 
meta-analysis of eight studies in 65,736 patients reported that the use of methotrexate was 
associated with a significant reduction in total cardiovascular events (RR 0.72, 95% CI 0.57 
to 0.91) [86]. Following the publication of these meta-analyses, a population-based 
retrospective study investigated the association between methotrexate treatment and risk of 
ischaemic stroke in rheumatoid arthritis (n=7,904). The use of methotrexate was associated 
with a lower risk of ischaemic stroke during the first seven years of follow-up (adjusted 
hazard ratio, HR, 0.33, 95% CI 0.17 to 0.63). However, it was also associated with a higher 
risk of ischaemic stroke during the following three years (adjusted HR 3.36, 95% CI 1.70 to 
6.61) [87]. A more recent observational study has specifically investigated the associations 
between methotrexate use and risk of cardiovascular events in 23,994 older patients with 
rheumatoid arthritis diagnosed after the age of 65 years. The use of methotrexate both in the 
previous 12 months and during the first year of follow-up was associated with a significant 
reduction in cardiovascular risk (HR, 0.79, 95% CI 0.70 to 0.88; and HR 0.84, 95% CI 0.72 to 
0.96, respectively). However, a longer methotrexate exposure did not have a significant effect 
on cardiovascular risk (HR 0.98, 95% CI 0.95 to 1.01) [88].  
In contrast with the overall results of observational studies, methotrexate treatment failed to 
show significant cardioprotective effects in a recent multicentre randomized placebo-
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controlled trial in patients with high cardiovascular risk but without autoimmune disorders. In 
this study, 4,786 patients with a previous history of myocardial infarction or multivessel 
coronary artery disease and concomitant type 2 diabetes or metabolic syndrome were 
randomized to methotrexate treatment (target weekly dose 15-20mg) or matching placebo. 
After a median follow-up period of 2.3 years, methotrexate treatment was not associated with 
a significant reduction in a composite end-point non-fatal myocardial infarction, non-fatal 
stroke, or cardiovascular death (HR 0.96, 95% CI 0.79 to 1.16) [89]. The results of this study 
need to be interpreted with caution as both patients randomized to methotrexate and those 
randomized to placebo received oral folic acid 1mg daily for the duration of the study [89]. 
Oral folic acid treatment has been shown to enhance endothelial function and reduce blood 
pressure and arterial stiffness in human studies [90-92]. These effects might have translated 
into a beneficial effect on cardiovascular risk, as recently documented in other studies [93, 
94]. Therefore, the administration of folic acid in the placebo group might have diluted the 
potential beneficial effects of methotrexate on cardiovascular risk in the active group.    
4.2 Methotrexate, endothelial function, arterial stiffness, and blood pressure 
Animal studies have shown conflicting results on the effects of methotrexate on endothelial 
function. Some studies reported negative effects [95, 96], whereas others described a 
significant improvement in endothelial function [97, 98]. However, the doses of methotrexate 
administered in these studies, between 24 and 490mg/day, are considerably higher than the 
doses typically prescribed in patients with autoimmune disorders, between 1 and 4mg/day. In 
human studies, methotrexate, singly or combined with other DMARDs, has been shown to 
enhance endothelial function in patients with inflammatory arthritis and rheumatoid arthritis 
[99-101].  
In a study in patients with rheumatoid arthritis, methotrexate treatment did not reduce arterial 
stiffness [102]. By contrast, in a repeated cross-sectional study of patients with rheumatoid 
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arthritis, methotrexate treatment was independently associated with reduced pulse-wave 
velocity, a marker of arterial stiffness, measured over 24 hours, after adjusting for age, 
gender, body mass index, rheumatoid arthritis disease severity and use of folic acid [103].    
Observational cross-sectional and prospective studies in rheumatoid arthritis have also shown 
that methotrexate use is associated with lower systolic and diastolic blood pressure and 
reduced incidence of hypertension, when compared to other DMARDs or no treatment [103-
108]. In one of these studies, the associations between methotrexate treatment and lower 
blood pressure were also observed for 24-hr measures of peripheral and central blood pressure 
[103]. Twenty-four-hour averages of systolic and diastolic blood pressure are significantly 
superior to clinical blood pressure in terms of cardiovascular risk stratification [109]. 
Furthermore, measures of central blood pressure can better explain, when compared to 
peripheral blood pressure, the effects of different blood pressure lowering strategies on 
cardiovascular end-points [110]. In other studies, methotrexate has been shown to prevent the 
temporal increase in blood pressure mediated by arterial stiffness in rheumatoid arthritis, a 
phenomenon also reported with advancing age [111-113]. 
Therefore, the results of human studies generally support the hypothesis that methotrexate 
might exert beneficial effects on endothelial function, arterial stiffness, and blood pressure in 
patients with rheumatoid arthritis. Given the described similarities in the pathophysiology of 
arterial wall dysfunction between rheumatoid arthritis and ageing, it is plausible that the 
putative vasculoprotective effects of methotrexate might also be biologically and clinically 
relevant in the older patient population. The following sections discuss the pharmacology of 
methotrexate and the possible mechanisms responsible for the vasculoprotective effects of 
this drug.    
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5. PUTATIVE MECHANISMS OF METHOTREXATE-MEDIATED 
VASCULOPROTECTION 
The intracellular polyglutamate forms of methotrexate inhibit the enzymes dihydrofolate 
reductase, thymidylate synthase, and aminoimidazole carboxamide ribonucleotide (AICAR) 
transformylase (ATIC) [114]. In particular, ATIC inhibition, with the consequent 
accumulation of the substrate AICAR, leads to the inhibition of the enzymes adenosine 
deaminase and adenosine monophosphate deaminases, responsible for the catabolism of 
adenosine (Figure 2) [115]. Adenosine is an important extracellular signalling molecule, with 
a half-life of a few seconds, that exerts significant anti-inflammatory effects through the A2A 
and A3 receptors [116]. These effects are likely to mediate the musculoskeletal anti-
inflammatory and immunomodulatory effects of methotrexate in rheumatoid arthritis and 
other autoimmune disorders. However, the anti-inflammatory actions of adenosine might also 
exert vasculoprotective effects by preventing the increase in vascular permeability and 
endothelial cell damage induced by inflammatory stimuli, inhibiting vascular smooth muscle 
cell proliferation and suppressing atherosclerosis in experimental models [117-120]. 
Furthermore, primarily through the A2A receptors, adenosine favours the opening of the Kv 
and KATP channels in vascular smooth muscle cells, with consequent membrane 
hyperpolarization, relaxation and vasodilation, and also stimulates NO synthesis by 
endothelial cells [121-123]. Although the direct vasodilatory effects of adenosine might 
account for the reported blood pressure lowering effects of this messenger, central 
mechanisms are also involved in the hypotensive response [124-126]. The role of adenosine 
in the regulation of blood pressure and arterial stiffness is further demonstrated by human 
studies showing that the pharmacological inhibition of the adenosine receptors A1 and A2A 
causes an acute increase in both parameters [127, 128]. Adenosine also inhibits the activity of 
the sino-atrial node, with a consequent reduction in heart rate [129, 130]. This phenomenon, 
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together with the additional bradycardic effects of adenosine mediated by the central nervous 
system, might also account for a reduction in arterial stiffness given the established effect of 
increasing heart rate on arterial stiffness both in animal models and in humans [126, 131-
133].   
The accumulation of AICAR, resulting from methotrexate-induced inhibition of ATIC, 
activates AMPK (Figure 2) [134]. Both AICAR and AMPK have been shown to stimulate 
endothelial NO synthesis and reduce blood pressure in experimental models [135-139]. 
AMPK might also play an important role in the regulation of arterial stiffness. This is 
supported by studies showing that the deficiency of the ageing-suppressor gene klotho 
accelerates the increase of arterial stiffness during a high-fat diet in mice, through the 
inhibition of AMPK expression [140]. By contrast, stimulation of AMPK prevents the 
increase in arterial stiffness in klotho-deficient mice [141].  
Recent studies also suggest that methotrexate, either directly or through AICAR accumulation 
and/or AMPK activation, can significantly reduce the expression and/or the concentrations of 
the pro-atherosclerotic cytokines, TNF-, IL-1, and IL-6. These cytokines have been shown 
to play an important role in favouring endothelial dysfunction, vascular damage, and 
atherosclerosis both in rheumatoid arthritis and in models of experimental ageing [142-145]. 
Therefore, the available in vitro and in vivo evidence supports the hypothesis that 
methotrexate might exert a unique combination of vasculoprotective effects through the 
accumulation of adenosine and AICAR, stimulation of AMPK, and down-regulation of TNF-
, IL-1, and IL-6 (Figure 3). However, further experimental and human investigations are 
warranted to establish the exact role of these biomarkers in mediating the effects of 
methotrexate treatment on surrogate and clinical cardiovascular end-points in intervention 
studies. 
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6. METHOTREXATE AND VASCULAR PROTECTION IN OLD AGE: 
PRACTICAL CONSIDERATIONS 
The routine use of methotrexate for cardiovascular risk management might represent an 
attractive treatment option in the older patient population for a number of reasons. Treatment 
with methotrexate is associated with gastroenterological, haematological, renal, neurological, 
pulmonary and mucocutaneous toxicity [146, 147]. However, with appropriate dosing and 
monitoring, serious adverse events are relatively infrequent both in observational studies and 
in randomized controlled trials, between 2.1-5.5% [148-150]. Furthermore, in a study that 
specifically investigated the safety of methotrexate in 33 older patients with rheumatoid 
arthritis (mean age 78.8 years) followed for two years, treatment was discontinued in two 
patients because of abnormal liver function tests and in other two patients because of 
gastrointestinal side effects. No serious adverse events were described in this study [151]. 
These data support the overall safety and tolerability of methotrexate treatment in older 
patients.  
A potential advantage of methotrexate treatment, particularly in a patient group that is often 
exposed to the unwanted consequences of inappropriate polypharmacy and complex 
medications regimens, is the once-weekly administration. This less intensive dosing regimen 
might ensure treatment adherence, which remains a significant issue in the routine 
management of cardiovascular risk in older patients [152, 153]. Furthermore, the key role of 
polyglutamates in mediating the vasculoprotective effects of methotrexate, if demonstrated in 
longitudinal studies, might translate into a favourable pharmacokinetic profile, in terms of 
treatment efficacy and safety, given the relatively long half-life of these intracellular forms of 
the drug [154]. This would ensure a sustained effect of methotrexate on vascular homeostasis 
and blood pressure in case of occasional dose missing. Furthermore, it would minimize the 
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risk of acute post-dose orthostatic hypotension, a frequent and potentially serious side effect 
of cardiovascular and non-cardiovascular medications in the older population [155]. 
However, the hypothesis that methotrexate can be repurposed for the management of 
cardiovascular risk in older patients needs to be robustly investigated in appropriately 
designed intervention studies, using either placebo or other DMARDs as comparator, in 
patients with different degrees of vascular dysfunction, combinations of risk factors, and 
residual inflammatory cardiovascular risk. Such trials should investigate the short- and long-
term effects of methotrexate on surrogate markers of vascular damage (e.g. endothelium-
dependent vasodilation, arterial stiffness, and blood pressure) as well as “hard” clinical end-
points (e.g. non-fatal myocardial infarction and stroke, cardiovascular mortality and all-cause 
mortality). The use of DMARDs or other anti-inflammatory agents as comparator is required 
to test whether methotrexate exerts vasculoprotective effects that are either independent of 
inflammation or are mediated by methotrexate-specific inflammatory targets. Additionally, 
intervention studies should assess whether the potential vasculoprotective effects of 
methotrexate are mediated by intracellular polyglutamates and/or genetic polymorphisms of 
methotrexate transporters and target enzymes [156]. 
 
7. CONCLUSIONS 
Patients with rheumatoid arthritis exhibit premature vascular ageing and have an increased 
cardiovascular risk in the context of a chronic systemic pro-inflammatory state. The 
identification of effective vasculoprotective therapies in rheumatoid arthritis might lead to 
their additional use in the older patient population, the main group suffering from the burden 
of atherosclerotic cardiovascular disease. Observational studies in patients with rheumatoid 
arthritis have shown that the DMARD methotrexate can reduce cardiovascular morbidity and 
mortality. In vitro and in vivo studies suggest that methotrexate might exert a unique 
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combination of anti-inflammatory and vasculoprotective effects through the accumulation of 
adenosine and AICAR, stimulation of AMPK, and down-regulation of TNF-, IL-1, and IL-6. 
However, adequately designed intervention studies are warranted to determine the exact role 
of methotrexate in cardiovascular risk management in the older patient population.    
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Figure legends 
Figure 1: Mechanisms mediating the increased cardiovascular risk in rheumatoid arthritis and 
advancing age. 
Figure 2: Intracellular effects of methotrexate. ATIC, aminoimidazole carboxamide 
ribonucleotide (AICAR) transformylase; FAICAR, 5-formamidoimidazole-4-carboxamide 
ribotide; IMP, inosine monophosphate; AMP, adenosine monophosphate; AMPK, 5' 
adenosine monophosphate-activated protein kinase; 5’-NT, 5’-nucleotidase; -, inhibition; +, 
activation. 
Figure 3: Putative mechanism mediating the potential vasculoprotective effects of 
methotrexate. AICAR, aminoimidazole carboxamide ribonucleotide; AMPK, 5' adenosine 
monophosphate-activated protein kinase; TNF, tumour necrosis factor, IL, interleukin. 
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